Literature DB >> 21692776

Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.

M M Mutizwa, D R Berk, M J Anadkat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21692776     DOI： 10.1111/j.1365-2133.2011.10476.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  14 in total

1.  Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas.

Authors:  Guillaume Le Guyader; Victoire Vieillard; Karine Andrieux; Mylène Rollo; Olivier Thirion; Pierre Wolkenstein; Muriel Paul
Journal:  Eur J Hosp Pharm       Date:  2018-11-10

2.  Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.

Authors:  Mari Wataya-Kaneda; Yuuki Ohno; Yasuyuki Fujita; Hiroo Yokozeki; Hironori Niizeki; Masaaki Ogai; Kazuyoshi Fukai; Hiroshi Nagai; Yuichi Yoshida; Izumi Hamada; Taihei Hio; Kenji Shimizu; Hiroyuki Murota
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

3.  Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.

Authors:  Mary Kay Koenig; Cynthia S Bell; Adelaide A Hebert; Joan Roberson; Joshua A Samuels; John M Slopis; Patti Tate; Hope Northrup
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

4.  Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex.

Authors:  Darcy A Krueger
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

Review 5.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

Review 6.  Targeted treatment trials for tuberous sclerosis and autism: no longer a dream.

Authors:  Mustafa Sahin
Journal:  Curr Opin Neurobiol       Date:  2012-05-04       Impact factor: 6.627

Review 7.  Rapamycin and rapalogs for tuberous sclerosis complex.

Authors:  Teguh H Sasongko; Nur Farrah Dila Ismail; Zamh Zabidi-Hussin
Journal:  Cochrane Database Syst Rev       Date:  2016-07-13

8.  Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.

Authors:  Mary Kay Koenig; Adelaide A Hebert; Joan Roberson; Joshua Samuels; John Slopis; Audrey Woerner; Hope Northrup
Journal:  Drugs R D       Date:  2012-09-01

9.  Topical rapamycin (sirolimus) for facial angiofibromas.

Authors:  Bhushan Madke
Journal:  Indian Dermatol Online J       Date:  2013-01

10.  Fibrous papule of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of rapamycin pathway: evidence for a novel therapeutic strategy?

Authors:  Jung-Yi Lisa Chan; Kuo-Hsien Wang; Chia-Lang Fang; Wei-Yu Chen
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.